Ignite Creation Date:
2025-12-24 @ 10:41 PM
Ignite Modification Date:
2026-07-09 @ 10:19 PM
Study NCT ID:
NCT03334435
Status:
COMPLETED
Last Update Posted:
2024-09-03
First Post:
2017-11-03
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis
Sponsor:
Eli Lilly and Company
Organization:
Study Overview
Official Title:
A Phase 3 Multicenter, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Adult Patients With Atopic Dermatitis
Status:
COMPLETED
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BREEZE-AD3
Brief Summary:
The purpose of this study is to evaluate the long-term safety and efficacy of baricitinib in participants with atopic dermatitis.
Participants were enrolled in this study from the originating studies (JAHL, JAHM, JAIY) or were directly enrolled in the open-label arm.
Participants were enrolled in this study from the originating studies (JAHL, JAHM, JAIY) or were directly enrolled in the open-label arm.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: